Navigation Links
Rhode Island Hospital study identifies fish oil's impact on cognition and brain structure

PROVIDENCE, R.I. Researchers at Rhode Island Hospital's Alzheimer's Disease and Memory Disorders Center have found positive associations between fish oil supplements and cognitive functioning as well as differences in brain structure between users and non-users of fish oil supplements. The findings suggest possible benefits of fish oil supplements on brain health and aging. The results were reported at the recent International Conference on Alzheimer's Disease, in Paris, France.

The study was led by Lori Daiello, PharmD, a research scientist at the Rhode Island Hospital Alzheimer's Disease and Memory Disorders Center. Data for the analyses was obtained from the Alzheimer's Disease Neuroimaging Initiative (ADNI), a large multi-center, NIH-funded study that followed older adults with normal cognition, mild cognitive impairment, and Alzheimer's Disease for over three years with periodic memory testing and brain MRIs.

The study included 819 individuals, 117 of whom reported regular use of fish oil supplements before entry and during study follow-up. The researchers compared cognitive functioning and brain atrophy for patients who reported routinely using these supplements to those who were not using fish oil supplements.

Daiello reports that compared to non-users, use of fish oil supplements was associated with better cognitive functioning during the study. However, this association was significant only in those individuals who had a normal baseline cognitive function and in individuals who tested negative for a genetic risk factor for Alzheimer's Disease known as APOE4. This is consistent with previous research.

The unique finding, however, is that there was a clear association between fish oil supplements and brain volume. Consistent with the cognitive outcomes, these observations were significant only for those who were APOE4 negative.

Daiello says, "In the imaging analyses for the entire study population, we found a significant positive association between fish oil supplement use and average brain volumes in two critical areas utilized in memory and thinking (cerebral cortex and hippocampus), as well as smaller brain ventricular volumes compared to non-users at any given time in the study. In other words, fish oil use was associated with less brain shrinkage in patients taking these supplements during the ADNI study compared to those who didn't report using them."

Daiello continues, "These observations should motivate further study of the possible effects of long-term fish oil supplementation on important markers of cognitive decline and the potential influence of genetics on these outcomes."

The research team included Brian Ott M.D., director of the Rhode Island Hospital and Memory Disorders Center, Assawin Gongvatana Ph.D., Shira Dunsiger Ph.D. and Ronald Cohen Ph.D. from The Miriam Hospital and the Brown University Department of Psychiatry and Human Behavior (Gonvatana and Cohen), and Department of Behavior and Social Sciences (Dunsiger).


Contact: Nancy Cawley Jean

Related medicine news :

1. Rhode Island and Miriam researchers say patient gender may influence nuclear stress test referrals
2. Rhode Island Hospital fellow receives funding to support research in myocardial perfusion
3. Paper by Rhode Island Hospital physician selected among best of 2010 by JACR
4. Women & Infants launches Rhode Island Network for Pelvic Floor Disorders
5. Rhode Island Hospital physician receives national award for research
6. Rhode Island Settlement Reflects Homeowner Liability for Serving Alcohol to Those Under 21, Says Providence Lawyer Mark Gemma
7. What will climate change and sea level rise mean for barrier islands?
8. Sea grant awards more than $1.1 million for research under EPAs Long Island Sound study
9. Scientists discover key to Christmas Islands red crab migration
10. Cyberknife of Long Island Destroys Prostate Cancer Non-Invasively Using Radiosurgery
11. Relevant Public Relations President Barton Horowitz of Staten Island, N.Y., Chamber CEO Linda Baran Applauded By Congressman McMahon as SBA Honorees
Post Your Comments:
(Date:6/25/2016)... ... ... closing of Bruton Memorial Library on June 21 due to a possible lice infestation, as ... of head lice: the parasite’s ability to live away from a human host, and to ... one in the event that lice have simply gotten out of control. , As lice ...
(Date:6/25/2016)... ... ... As a lifelong Southern Californian, Dr. Omkar Marathe earned his Bachelors in ... School of Medicine at UCLA. He trained in Internal Medicine at Scripps Green Hospital ... at the UCLA-Olive View-Cedars Sinai program where he had the opportunity to train in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the ... In terms of the latter, setting the bar too high can result in disappointment, ... just slow progress toward their goal. , Research from reveals ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... June 19, ... the dangers associated with chronic pain and the benefits of holistic treatments, Serenity ... who are suffering with Sickle Cell Disease. , Sickle Cell Disease (SCD) is a ...
(Date:6/24/2016)... Fla. (PRWEB) , ... June 24, 2016 , ... Global ... Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this recognition ... Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this year’s ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...  Arkis BioSciences, a leading innovator in the ... cerebrospinal fluid treatments, today announced it has secured ... led by Innova Memphis, followed by Angel Capital ... Arkis, new financing will accelerate the commercialization of ... of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... 23, 2016 Capricor Therapeutics, ... a biotechnology company focused on the discovery, development ... patient enrollment in its ongoing randomized HOPE-Duchenne clinical ... 50% of its 24-patient target. Capricor expects the ... quarter of 2016, and to report top line ...
Breaking Medicine Technology: